PHR Stock - Phreesia, Inc.
Unlock GoAI Insights for PHR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $419.81M | $356.30M | $280.91M | $213.23M | $148.68M |
| Gross Profit | $284.88M | $232.29M | $171.64M | $131.84M | $96.29M |
| Gross Margin | 67.9% | 65.2% | 61.1% | 61.8% | 64.8% |
| Operating Income | $-58,097,000 | $-136,479,000 | $-176,552,000 | $-116,817,000 | $-25,671,000 |
| Net Income | $-58,527,000 | $-136,885,000 | $-176,146,000 | $-118,161,000 | $-27,292,000 |
| Net Margin | -13.9% | -38.4% | -62.7% | -55.4% | -18.4% |
| EPS | $-1.02 | $-2.51 | $-3.36 | $-2.37 | $-0.69 |
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $26 |
| November 13th 2025 | BMO Capital Markets | Initiation | Outperform | $32 |
| September 5th 2025 | DA Davidson | Resumed | Buy | $33 |
| August 27th 2025 | Mizuho | Initiation | Outperform | $36 |
| January 8th 2025 | RBC Capital Mkts | Upgrade | Outperform | $32← $24 |
| February 26th 2024 | Truist | Initiation | Buy | $35 |
| January 17th 2024 | DA Davidson | Upgrade | Buy | $32← $30 |
| January 3rd 2024 | Barclays | Initiation | Overweight | $29 |
| April 12th 2023 | Stephens | Initiation | Overweight | $37 |
| January 4th 2023 | Needham | Reiterated | Buy | $40← $35 |
| December 13th 2022 | Citigroup | Upgrade | Buy | $40 |
| December 9th 2022 | SVB Leerink | Upgrade | Outperform | $34← $31 |
| October 13th 2022 | DA Davidson | Initiation | Neutral | $25 |
| September 16th 2022 | KeyBanc Capital Markets | Initiation | Overweight | $40 |
| April 14th 2022 | Guggenheim | Initiation | Buy | $45 |
Earnings History & Surprises
PHREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 26, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | $0.08 | — | — | — |
Q4 2025 | Dec 8, 2025 | $-0.00 | $0.10 | +27877.8% | ✓ BEAT |
Q3 2025 | Sep 4, 2025 | $-0.07 | $0.01 | +114.3% | ✓ BEAT |
Q2 2025 | May 28, 2025 | $-0.13 | $-0.07 | +46.2% | ✓ BEAT |
Q1 2025 | Mar 12, 2025 | $-0.19 | $-0.11 | +42.1% | ✓ BEAT |
Q4 2024 | Dec 9, 2024 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q3 2024 | Sep 4, 2024 | $-0.37 | $-0.31 | +16.2% | ✓ BEAT |
Q2 2024 | May 30, 2024 | $-0.51 | $-0.35 | +31.4% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.58 | $-0.56 | +3.4% | ✓ BEAT |
Q4 2023 | Dec 5, 2023 | $-0.72 | $-0.58 | +19.4% | ✓ BEAT |
Q3 2023 | Sep 6, 2023 | $-0.75 | $-0.68 | +9.3% | ✓ BEAT |
Q2 2023 | May 31, 2023 | $-0.80 | $-0.70 | +12.5% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.78 | $-0.72 | +7.7% | ✓ BEAT |
Q4 2022 | Dec 8, 2022 | $-0.88 | $-0.76 | +13.6% | ✓ BEAT |
Q3 2022 | Sep 7, 2022 | $-0.99 | $-0.89 | +10.1% | ✓ BEAT |
Q2 2022 | Jun 2, 2022 | $-1.09 | $-0.99 | +9.2% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-1.05 | $-0.90 | +14.3% | ✓ BEAT |
Q4 2021 | Dec 8, 2021 | $-0.47 | $-0.71 | -51.1% | ✗ MISS |
Q3 2021 | Sep 1, 2021 | $-0.22 | $-0.48 | -118.2% | ✗ MISS |
Latest News
Barclays Maintains Overweight on Phreesia, Lowers Price Target to $24
➖ NeutralMizuho Maintains Outperform on Phreesia, Lowers Price Target to $28
➖ NeutralBaird Maintains Outperform on Phreesia, Lowers Price Target to $25
➖ NeutralCitigroup Maintains Buy on Phreesia, Lowers Price Target to $29
➖ NeutralCanaccord Genuity Maintains Buy on Phreesia, Lowers Price Target to $33
➖ NeutralPhreesia shares are trading lower after JP Morgan maintained an Overweight rating on the stock and lowered its price target from $32 to $29.
📉 NegativeJP Morgan Maintains Overweight on Phreesia, Lowers Price Target to $29
➖ NeutralBarclays Initiates Coverage On Phreesia with Overweight Rating, Announces Price Target of $26
📈 PositivePhreesia Narrows FY2026 Sales Guidance from $472.000M-$482.000M to $479.000M-$481.000M vs $478.148M Est
➖ NeutralPhreesia Q3 EPS $0.07 Misses $0.24 Estimate, Sales $120.333M Beat $120.052M Estimate
📉 NegativeNeedham Reiterates Buy on Phreesia, Maintains $35 Price Target
📈 PositiveDA Davidson Maintains Buy on Phreesia, Raises Price Target to $35
📈 PositivePHR stock has given up its prior gain. Phreesia shares were trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and a $32 price target.
📈 PositivePhreesia shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and a $32 price target.
📈 PositiveBMO Capital Initiates Coverage On Phreesia with Outperform Rating, Announces Price Target of $32
📈 PositiveKeybanc Maintains Overweight on Phreesia, Lowers Price Target to $32
➖ NeutralTruist Securities Maintains Buy on Phreesia, Raises Price Target to $36
📈 PositiveJMP Securities Maintains Market Outperform on Phreesia, Raises Price Target to $34
📈 PositiveCanaccord Genuity Maintains Buy on Phreesia, Raises Price Target to $38
📈 PositivePhreesia shares are trading lower. The company reported Q2 financial results.
📉 NegativeFrequently Asked Questions about PHR
What is PHR's current stock price?
What is the analyst price target for PHR?
What sector is Phreesia, Inc. in?
What is PHR's market cap?
Does PHR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PHR for comparison